Effectiveness of Oral Hyaluronic Acid in Knee Osteoarthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04352322|
Recruitment Status : Completed
First Posted : April 20, 2020
Last Update Posted : April 20, 2020
|Condition or disease||Intervention/treatment||Phase|
|Knee Osteoarthritis||Dietary Supplement: A+HA(tm) Dietary Supplement: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||47 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effectiveness of Oral Hyaluronic Acid (A+ HA(tm), TOP Pharm.) in Knee Osteoarthritis: Clinical Trial|
|Actual Study Start Date :||January 2012|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2016|
20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
Dietary Supplement: A+HA(tm)
oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
Placebo Comparator: Placebo
20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
Dietary Supplement: Placebo
oral solution with no active ingredients
- WOMAC [ Time Frame: 8 weeks ]Mean change from baseline to 8 weeks. The higher the score, the greater the severity.
- SF-36 [ Time Frame: 8 weeks ]Mean change from baseline to 8 weeks. A higher score indicates a better QoL.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04352322
|TOP Pharm. & Medicalware|
|Principal Investigator:||Shyu-Jye Wang, MD||China Medical University Hospital|